Nautilus Capital Lease Obligations from 2010 to 2025
| NAUT Stock | USD 1.71 0.06 3.39% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 39.8 M | Current Value 27.4 M | Quarterly Volatility 13.5 M |
Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.12. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.
Nautilus | Capital Lease Obligations |
Latest Nautilus Biotechnology's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Nautilus Biotechnology over the last few years. Nautilus Biotechnology capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Nautilus Biotechnology asset purchases. For example, Nautilus Biotechnology can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Nautilus Biotechnology control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Nautilus Biotechnology's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nautilus Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Nautilus Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 13,423,127 | |
| Geometric Mean | 8,667,111 | |
| Coefficient Of Variation | 100.45 | |
| Mean Deviation | 11,891,174 | |
| Median | 4,775,000 | |
| Standard Deviation | 13,483,832 | |
| Sample Variance | 181.8T | |
| Range | 35M | |
| R-Value | 0.79 | |
| Mean Square Error | 71.7T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | 2,250,985 | |
| Total Sum of Squares | 2727.2T |
Nautilus Capital Lease Obligations History
About Nautilus Biotechnology Financial Statements
Nautilus Biotechnology shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Nautilus Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Nautilus Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nautilus Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 39.8 M | 27.4 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.